{"title":"Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study.","authors":"Gaku Shimane, Minoru Kitago, Hiroshi Yagi, Yuta Abe, Yasushi Hasegawa, Shutaro Hori, Masayuki Tanaka, Junya Tsuzaki, Yoichi Yokoyama, Yohei Masugi, Ryo Takemura, Yuko Kitagawa","doi":"10.1245/s10434-024-16851-z","DOIUrl":"10.1245/s10434-024-16851-z","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant therapy is recommended for treating resectable pancreatic ductal adenocarcinoma (PDAC); however, its appropriate use in patients with resectable PDAC remains debatable.</p><p><strong>Objective: </strong>This study aimed to identify independent poor prognostic factors and evaluate the clinical significance of neoadjuvant therapy in patients with resectable PDAC.</p><p><strong>Methods: </strong>We retrospectively reviewed consecutive patients diagnosed with resectable PDAC at our institute between January 2003 and December 2022. We analyzed poor prognostic factors at the time of diagnosis in patients who underwent upfront surgery using the Cox proportional hazards model for overall survival (OS). The prognostic score was calculated by adding the individual prognostic factor scores.</p><p><strong>Results: </strong>Overall, 359 patients were included in this study, with 308 patients undergoing upfront surgery and the remaining 51 patients receiving neoadjuvant therapy. The R0 resection rate was significantly higher in the neoadjuvant therapy group (70.6%) than in the upfront surgery group (64.0%). Multivariate analysis in the upfront surgery group revealed the following independent poor prognostic factors: tumor size ≥ 35 mm, serum albumin level ≤ .5 g/dL, neutrophil-to-lymphocyte ratio ≥ 3.5, carbohydrate antigen 19-9 level ≥ 250 U/mL, and Duke pancreatic monoclonal antigen type 2 level ≥ 750 U/mL. Among patients with prognostic scores of 0-1 (n = 263), the intention-to-treat OS did not significantly differ between the neoadjuvant therapy and upfront surgery groups. Among those patients with a prognostic score of ≥ 2 (n = 96), the neoadjuvant therapy group had significantly longer intention-to-treat OS than the upfront surgery group.</p><p><strong>Conclusions: </strong>Prognostic score-based stratification can help identify patients who could benefit from neoadjuvant therapy.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2830-2840"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ioannis Liapis, Alfonsus Adrian H Harsono, Jaspinder Sanghera, Katie West, Rida Ahmad, Michelle Holland, Larry Hearld, Smita Bhatia, Krista Mehari, Martin Heslin, Daniel I Chu, Annabelle L Fonseca
{"title":"ASO Visual Abstract: Patient-Reported Barriers to Foregut Cancer Care in the Deep South.","authors":"Ioannis Liapis, Alfonsus Adrian H Harsono, Jaspinder Sanghera, Katie West, Rida Ahmad, Michelle Holland, Larry Hearld, Smita Bhatia, Krista Mehari, Martin Heslin, Daniel I Chu, Annabelle L Fonseca","doi":"10.1245/s10434-025-17244-6","DOIUrl":"https://doi.org/10.1245/s10434-025-17244-6","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Susan J Kim, Chengli Shen, Mohamad El Moheb, Kaelyn C Cummins, Samantha M Ruff, Russell Witt, Allan Tsung
{"title":"ASO Visual Abstract: Sociodemographic Disparities in Rectal Cancer Outcomes within Academic Cancer Centers.","authors":"Susan J Kim, Chengli Shen, Mohamad El Moheb, Kaelyn C Cummins, Samantha M Ruff, Russell Witt, Allan Tsung","doi":"10.1245/s10434-025-17217-9","DOIUrl":"https://doi.org/10.1245/s10434-025-17217-9","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maurits R Visser, Daan M Voeten, Suzanne S Gisbertz, Jelle P Ruurda, Richard van Hillegersberg, Mark I van Berge Henegouwen
{"title":"Outcomes of Salvage Surgery for Esophageal Carcinoma: A Nationwide Cohort Study from the Dutch Upper GI Cancer Audit.","authors":"Maurits R Visser, Daan M Voeten, Suzanne S Gisbertz, Jelle P Ruurda, Richard van Hillegersberg, Mark I van Berge Henegouwen","doi":"10.1245/s10434-024-16490-4","DOIUrl":"10.1245/s10434-024-16490-4","url":null,"abstract":"<p><strong>Background: </strong>Salvage esophagectomy is more complex and associated with higher postoperative morbidity and mortality than standard resection. This study aimed to investigate short-term outcomes and the influence of hospital volume on these outcomes of salvage surgery for esophageal cancer.</p><p><strong>Methods: </strong>The study enrolled all patients undergoing esophagectomy for esophageal cancer registered in the Dutch Upper Gastrointestinal Cancer Audit (DUCA) between 2012 and 2022. The patients were classified as salvage or non-salvage by registering surgeons. Salvage surgery is defined in the DUCA as surgery after definitive chemoradiotherapy. Postoperative mortality (30-day/in-hospital) and morbidity were compared between the salvage and non-salvage patients using multilevel logistic regression analyses. Hospital variation in the use of salvage esophagectomy was investigated using funnel plots. The influence of hospital volume (≤ 40 to > 40 cases) and salvage volume (< 6 to ≥ 6 cases) on outcomes for salvage patients were investigated. Using backward elimination, relevant baseline characteristics influencing salvage outcomes were identified.</p><p><strong>Results: </strong>Between 2012 and 2022, 7749 patients underwent esophagectomy, 251 (3%) of whom underwent salvage resection, varying from 0 to 8% between centers. Severe complications (43% vs 28%; odds ratio [OR], 1.81; 95 % confidence interval [CI], 1.40-2.34) and 30-day/in-hospital mortality (11% vs 3%; OR, 3.65; 95% CI, 2.38-5.61) were higher after salvage surgery than after non-salvage surgery. Salvage patients treated in high-volume centers had a lower risk of 30-day/in-hospital mortality than those treated in low-volume centers (9% vs 19%; OR, 0.42; 95% CI, 0.18-0.99), with no relation between salvage volume and outcome. Male sex, older age (> 75 years), and squamous cell carcinoma were associated with worse short-term outcomes of salvage surgery.</p><p><strong>Conclusions: </strong>Salvage surgery is associated with worse short-term outcomes than non-salvage esophagectomy. Outcomes after salvage surgery were favorable in high-volume esophagectomy centers.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2687-2697"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Winy Widjaja, Irene Ng, Nicolas Shannon, N Gopalakrishna Iyer
{"title":"Neoadjuvant Immunotherapy in Resectable HNSCC: An Updated Systematic Review and Meta-analysis.","authors":"Winy Widjaja, Irene Ng, Nicolas Shannon, N Gopalakrishna Iyer","doi":"10.1245/s10434-024-16587-w","DOIUrl":"10.1245/s10434-024-16587-w","url":null,"abstract":"<p><strong>Background: </strong>Immunotherapy is a recently recognised FDA-approved treatment for R/M HNSCC. Our goal is to explore the safety profile and the efficacy of immunotherapy in the neoadjuvant setting before surgery in mucosal head and neck cancer.</p><p><strong>Methods: </strong>Three electronic databases had been systematically searched through March 2024. Demographic and tumour characteristics were extracted. Primary outcomes obtained were disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), complete pathological response (cPR), which was defined as no residual tumour, and major pathological response (MPR), which as defined as <10% residual viable tumour. Safety outcomes examined were grade 3 and above adverse event, median time to surgery, delays to surgery, and death related to neoadjuvant treatment.</p><p><strong>Results: </strong>A total of 459 patients from 15 studies were included in the analysis. The pooled estimate of cPR for all the studies was 14.9% (95% confidence interval [CI] 8.0-26.2). Subgroup analysis showed chemoimmunotherapy had a higher cPR 30.1% (95% CI 22.8-38.62) compared with immunotherapy alone 1.4% (95% CI 0.3-5.2). There was no treatment-related death. Chemoimmunotherapy had a higher pooled estimate of adverse events 22.9% (95% CI 11.0-41.5) compared with immunotherapy alone 8.5% (95% CI 2.6-24.3). Subgroup analysis demonstrated that chemoimmunotherapy had a higher DFS compared with immunotherapy alone: 89.8% (95% CI 81.4-94.7) versus 80.44% (95% CI 73.9-85.7), respectively. Neoadjuvant immunoradiotherapy had conflicting results.</p><p><strong>Conclusions: </strong>Neoadjuvant immunotherapy was well tolerated. Neoadjuvant chemoimmunotherapy may be more effective in treating LAHNSCC over immunotherapy alone; however, TRAEs were higher.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2713-2724"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Boyou Zhang, Lilong Xia, Xinhai Zhu, Lei Zhang, Chuanchuan Li, Lijia Wang, Zhengfu He
{"title":"Enhancing Respiration Function Evaluation and Recovery in Lung Cancer: The Interdisciplinary Approach to Postoperative Management.","authors":"Boyou Zhang, Lilong Xia, Xinhai Zhu, Lei Zhang, Chuanchuan Li, Lijia Wang, Zhengfu He","doi":"10.1245/s10434-024-16733-4","DOIUrl":"10.1245/s10434-024-16733-4","url":null,"abstract":"<p><p>We highlight the potential for further analysis and investigation of the article by Sirakaya and colleagues. Specifically, we note that the authors failed to evaluate diaphragm mobility, which is essential for a comprehensive assessment of respiratory function, as well as diaphragm thickness. Assessing diaphragm mobility could enrich our understanding of the impact of surgical approaches on respiratory mechanics and postoperative pulmonary complications. Additionally, we note the absence of socioeconomic status (SES) as a confounding factor in the study. Recognizing the influence of SES on surgical outcomes and patient recovery, we suggest its inclusion in future research. We also emphasize the importance of integrating a multidisciplinary team, including physiotherapists and social workers, to address the physical and socioeconomic challenges faced by patients post-surgery.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2710-2711"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nolan M Winicki, Fabian M Johnston, Jonathan B Greer
{"title":"ASO Author Reflections: Advancing Post-operative Infection Risk Assessment of CRS/HIPEC with Splenectomy.","authors":"Nolan M Winicki, Fabian M Johnston, Jonathan B Greer","doi":"10.1245/s10434-024-16825-1","DOIUrl":"10.1245/s10434-024-16825-1","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2934-2935"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marcos R Gonzalez, Ashlyn S Morse, Hyunwoo P Kang, Santiago A Lozano-Calderon
{"title":"ASO Author Reflections: Comparison of Percutaneous Techniques for Stabilization of Osteolytic Lesions of the Periacetabular Region Due to Metastatic Bone Disease.","authors":"Marcos R Gonzalez, Ashlyn S Morse, Hyunwoo P Kang, Santiago A Lozano-Calderon","doi":"10.1245/s10434-024-16809-1","DOIUrl":"10.1245/s10434-024-16809-1","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2983-2985"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pietro Addeo, Milena Muzzolini, Christophe Laurent, Bruno Heyd, Alain Sauvanet, Jonathan Garnier, Marie Sophie Alfano, Sebastien Gaujoux, Charles De Ponthaud, Ugo Marchese, Doris Da Silva, Emmanuel Buc, Regis Souche, Jean Michel Fabre, Pierre-Emanuel Colombo, Lorenzo Ferre, Maxime Foguenne, Catherine Hubert, Mehdi El Amrani, Stephanie Truant, Lilian Schwartz, Nicolas Regenet, Aurelien Dupre, Raffaele Brustia, Rim Cherif, Julie Navez, Benjamin Darnis, Olivier Facy, Robin Grellet, Guillaume Piessen, Julie Veziant, Rami Rhaiem, Reza Kianmanesh, Elena Fernandez-De-Sevilla, Maximiliano Gelli, Abdelkader Taibi, Pauline Georges, Jean Yves Mabrut, Mickael Lesurtel, Alexandre Doussot, Philippe Bachellier
{"title":"Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study.","authors":"Pietro Addeo, Milena Muzzolini, Christophe Laurent, Bruno Heyd, Alain Sauvanet, Jonathan Garnier, Marie Sophie Alfano, Sebastien Gaujoux, Charles De Ponthaud, Ugo Marchese, Doris Da Silva, Emmanuel Buc, Regis Souche, Jean Michel Fabre, Pierre-Emanuel Colombo, Lorenzo Ferre, Maxime Foguenne, Catherine Hubert, Mehdi El Amrani, Stephanie Truant, Lilian Schwartz, Nicolas Regenet, Aurelien Dupre, Raffaele Brustia, Rim Cherif, Julie Navez, Benjamin Darnis, Olivier Facy, Robin Grellet, Guillaume Piessen, Julie Veziant, Rami Rhaiem, Reza Kianmanesh, Elena Fernandez-De-Sevilla, Maximiliano Gelli, Abdelkader Taibi, Pauline Georges, Jean Yves Mabrut, Mickael Lesurtel, Alexandre Doussot, Philippe Bachellier","doi":"10.1245/s10434-024-16735-2","DOIUrl":"10.1245/s10434-024-16735-2","url":null,"abstract":"<p><strong>Background: </strong>The use of multiagent FOLFIRINOX chemotherapy for pancreatic adenocarcinoma in a neoadjuvant setting has been associated with an increased rate of complete pathological response (CPR) after surgery. This study investigated the long-term outcomes of patients with CPR in a multicenter setting to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS).</p><p><strong>Methods: </strong>This retrospective cohort study examined biopsy-proven pancreatic adenocarcinomas with CPR after neoadjuvant chemotherapy or chemoradiotherapy and surgery, between January 2006 and December 2023 across 22 French and 2 Belgian centers. Cox analyses were used to identify prognostic factors of OS and RFS.</p><p><strong>Results: </strong>There were 101 patients with CPR after chemotherapy (n = 58, 57.4%) and chemoradiotherapy (n = 43, 42.6%) followed by surgery. Neoadjuvant FOLFIRINOX was used in 90% of patients. The median OS after surgery was 177 months (95% confidence interval (CI) 58.9-177 months) with 1-, 3-, 5-, and 10-year OS rates of 93%, 75%, 63%, and 51%, respectively. The median RFS was 67.8 months (95% CI:34.4-NR) with 1-, 3-, 5-, and 10-year RFS rates of 83%, 58%, 54%, and 49%, respectively. The multivariate Cox analysis of OS and RFS showed that preoperative radiotherapy was an independent negative prognostic factor for OS (hazard ratio (HR) 2.51; 95% CI 1.00-6.30; p = 0.03) and RFS (HR 2.62; 95% CI 1.27-5.41; p = 0.009).</p><p><strong>Conclusions: </strong>Complete pathologic response after neoadjuvant treatment is associated with remarkable long-term survival that is usually not seen after the resection of pancreatic adenocarcinomas. One-third of the patients still experienced disease recurrence, which was more common in those receiving preoperative chemoradiotherapy.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2809-2818"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142943268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"ASO Author Reflections: Real Anatomical Right Hepatectomy Preserving the Caudate Lobe: Advancing Precision in Liver Surgery.","authors":"Ji Hoon Kim, Hyeong Min Park","doi":"10.1245/s10434-025-16887-9","DOIUrl":"10.1245/s10434-025-16887-9","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2487-2488"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}